MIRA PHARMACEUTICALS, INC. COMMON STOCK (NASDAQ: MIRA)

MIRA PHARMACEUTICALS, INC. COMMON STOCK

NASDAQ: MIRA (MIRA Pharmaceuticals, Inc.)

最近更新时间: 25 Aug, 12:58AM

1.43

0.03 (2.14%)

加入群组

前收盘价格	1.40
收盘价格	1.40
成交量	171,063
平均成交量 (3个月)	1,330,335
市值	27,269,098

股市价格/股市净资产 (P/B)

44.84

52周波幅

0.730 (-48%) — 2.70 (88%)

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看涨	看跌
	Drug Manufacturers - General (全球的)	看涨	看跌
股票	MIRA Pharmaceuticals, Inc.	混合的	混合的

AIStockmoo 评分

1.1

分析师共识	2.0
内部交易活动	NA
价格波动	-2.0
技术平均移动指标	5.0
技术振荡指标	-0.5
平均	1.13

相关股票

股票	市值	DY	P/E（TTM）	P/B
MIRA	27 M	-	-	44.84
AMRN	400 M	-	-	0.740
SCLXW	-	-	-	-
AZN	236 B	2.08%	28.44	5.80
SNY	118 B	4.58%	16.37	1.49
AMGN	159 B	3.17%	24.20	19.78

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
部门	Healthcare
行业	Drug Manufacturers - General
内部持股比例	19.68%
机构持股比例	5.60%

所有权

姓名	日期	持有股份
Suncoast Equity Management	30 Jun 2025	103,289
First American Bank	30 Jun 2025	20,000
Cary Street Partners Financial Llc	30 Jun 2025	10,000

该时间范围内无数据。

日期	类型	细节
30 Sep 2025	公告	MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
22 Sep 2025	公告	MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
16 Sep 2025	公告	MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
12 Sep 2025	公告	MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
19 Aug 2025	公告	MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
12 Aug 2025	公告	MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
30 Jul 2025	公告	MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
29 Jul 2025	公告	MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
11 Jul 2025	公告	MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

总债务/股东权益 (D/E MRQ)	0.04%
流动比率 (MRQ)	12.85
营业现金流 (OCF TTM)	-6.14 M
杠杆自由现金流 (LFCF TTM)	-3.26 M

资产报酬率 (ROA TTM)	-193.30%
股东权益报酬率 (ROE TTM)	-355.82%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)